GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Insider Ownership

ValiRx (LSE:VAL) Insider Ownership : 31.78 % (As of May. 11, 2024)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ValiRx's insider ownership is 31.78%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ValiRx's Institutional Ownership is 35.40%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ValiRx's Float Percentage Of Total Shares Outstanding is 0.00%.


ValiRx Insider Ownership Historical Data

The historical data trend for ValiRx's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Insider Ownership Chart

ValiRx Historical Data

The historical data trend for ValiRx can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Insider Ownership 30.04 30.04 30.04 30.04 30.04 30.04 30.82 30.82 30.82 31.78

ValiRx Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


ValiRx (LSE:VAL) Business Description

Traded in Other Exchanges
Address
4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.